<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32094">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688855</url>
  </required_header>
  <id_info>
    <org_study_id>PS-607</org_study_id>
    <nct_id>NCT02688855</nct_id>
  </id_info>
  <brief_title>CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures</brief_title>
  <official_title>Prospective, Randomized, Double-Blinded, Controlled Multi-Center Clinical Trial Evaluating the Use of Non-Invasive CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Encore Medical, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Encore Medical, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OL1000 is intended to be used as a non-invasive adjunctive treatment for adult males or
      females that have sustained a closed, unstable ankle fracture that requires surgical
      treatment for stabilization. The initiation of the adjunctive treatment is to begin within
      11 days of surgical stabilization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change overtime of Olerud and Molander Ankle Score (OMAS)</measure>
    <time_frame>6 weeks, 8 weeks, 10 weeks and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-powered, composite safety endpoint consisting of: Joint Position Outcome Radiographic Failure and Repeat, Unplanned Surgery at the Operative Site and Device-Related Serious Adverse Events</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">217</enrollment>
  <condition>Bimalleolar Ankle Fractures</condition>
  <arm_group>
    <arm_group_label>Investigational Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Rigid Fixation + Active OL1000 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard Rigid Fixation + Sham OL1000 device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Combined Magnetic Field OL1000 Bone Growth Stimulator</intervention_name>
    <description>Active CMF OL1000 Device</description>
    <arm_group_label>Investigational Group</arm_group_label>
    <other_name>CMF OL1000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Combined Magnetic Field OL1000 Bone Growth Stimulator</intervention_name>
    <description>Sham CMF OL1000</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>CMF OL1000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is diagnosed with an unstable, closed, isolated fracture of the ankle and
             underwent operative stabilization with plate(s) and/or screws (Weber Ankle Fracture
             Classification B and C)

        Exclusion Criteria:

          -  Subject has an open fracture

          -  Subject has any additional fractures of another bone besides the ankle fracture that
             is to be treated in the study including the contralateral ankle

          -  Surgical stabilization was definitively performed with an external fixation system

          -  Surgical stabilization was performed in such a manner that it will result in a fusion
             of the ankle joint

          -  Malreduced Ankle as described by Phillips, et al 1985 JBJS

          -  Surgical procedure included the use of osteoinductive materials in addition to rigid
             fixation

          -  BMI â‰¥ 40 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rutgers Biomedical Health Sciences</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheldon Lin, MD</last_name>
      <phone>973-972-2184</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Judd, MD</last_name>
      <phone>585-276-7790</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.djoglobal.com/products/cmf/cmf-ol1000</url>
  </link>
  <results_reference>
    <citation>Phillips WA, Schwartz HS, Keller CS, Woodward HR, Rudd WS, Spiegel PG, Laros GS. A prospective, randomized study of the management of severe ankle fractures. J Bone Joint Surg Am. 1985 Jan;67(1):67-78.</citation>
    <PMID>3881447</PMID>
  </results_reference>
  <results_reference>
    <citation>Olerud C, Molander H. A scoring scale for symptom evaluation after ankle fracture. Arch Orthop Trauma Surg. 1984;103(3):190-4.</citation>
    <PMID>6437370</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>February 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Growth Stimulator</keyword>
  <keyword>Ankle Fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Ankle Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
